Not applicableStudy completedNCT03718117What this trial is testingDescriptive Observational Study ALK-2016-CPHGWho this might be right forNSCLCCrizotinibALK Gene Rearrangement or ROS1 Gene Rearrangement Pfizer 73
Not applicableStudy completedNCT05792644What this trial is testingTherapeutic Effect of Crizotinib for Rearrangement-negative, High Phosphorylated ALK PatientsWho this might be right forALK Phosphorylation Harbin Medical University 15
Testing effectiveness (Phase 2)UnknownNCT04292119What this trial is testingLorlatinib Combinations in Lung CancerWho this might be right forLung CancerAnaplastic Lymphoma Kinase Gene TranslocationROS1 Rearrangement+4 more Massachusetts General Hospital 96
Testing effectiveness (Phase 2)Ended earlyNCT02186821What this trial is testingCeritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)Who this might be right forTumors With Aberrations in ALK or ROS1 Novartis Pharmaceuticals 47
Not applicableNot Yet RecruitingNCT07045610What this trial is testingPrimary Resistance Mechanisms of ALK TKIsWho this might be right forALK-positive Advanced NSCLC PatientsPrimary ResistanceNGS National Taiwan University Hospital 20
Testing effectiveness (Phase 2)Study completedNCT01562015What this trial is testingGanetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)Who this might be right forNon Small Cell Lung Cancer Synta Pharmaceuticals Corp. 12